Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss

To assess the effects of aspirin or heparin (including low-molecular-weight heparins), or both for improving pregnancy outcome in women with persistent (on two occasions not less than 12 weeks apart) APLA, either LAC, aCL or aβ2 antibodies or a combination and recurrent pregnancy loss (miscarriage or fetal loss).

This is a protocol.